Eisai loses DEA battle

Share this article:

Eisai's legal maneuver to pressure the DEA to schedule its FDA-approved epilepsy drug has failed. BioCentury reports that the District of Columbia's US Court of Appeals will not compel the Drug Enforcement Agency to put the seizure medication, Fycompa, on a schedule within a given time frame.

Without a designated schedule, Eisai cannot put the drug on the market, even though the patent life continues to wind down.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters